AN2 Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period
AN2 Therapeutics, Inc. (ANTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period of 524.03 thousand shares for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-13.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod · last filed 2024-11-13
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-09-30 was 489.83K shares, a 819.58% increase year-over-year.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-06-30 was 0.00 shares.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2024-03-31 was 34.20K shares.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for the quarter ending 2023-12-31 was 22.60K shares.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2023 was 75.87K shares, a 138.34% increase from fiscal 2022.
- AN2 Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures in period for fiscal 2022 was 31.83K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period 12 month |
|---|---|---|---|---|
| 2024-09-30 | 489.83K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | 489.83K shares derived: sum of 2 quarters · filed 2024-11-13 | 524.03K shares 10-Q · filed 2024-11-13 | 546.63K shares derived: sum of 4 quarters · filed 2024-11-13 |
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 34.20K shares 10-Q · filed 2024-08-13 | 56.80K shares derived: sum of 3 quarters · filed 2024-08-13 | 110.07K shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 34.20K shares 10-Q · filed 2024-05-14 | 56.80K shares derived: sum of 2 quarters · filed 2024-05-14 | 110.07K shares derived: sum of 3 quarters · filed 2024-05-14 | 110.07K shares derived: sum of 4 quarters · filed 2024-05-14 |
| 2023-12-31 | 22.60K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | 75.87K shares derived: sum of 2 quarters · filed 2024-03-29 | 75.87K shares derived: sum of 3 quarters · filed 2024-03-29 | 75.87K shares 10-K · filed 2024-03-29 |
| 2023-09-30 | 53.27K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 53.27K shares derived: sum of 2 quarters · filed 2023-11-09 | 53.27K shares 10-Q · filed 2023-11-09 | 53.27K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 0.00 shares 10-Q · filed 2023-08-10 | 0.00 shares derived: sum of 3 quarters · filed 2023-08-10 | 0.00 shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 0.00 shares 10-Q · filed 2023-05-11 | 0.00 shares derived: sum of 2 quarters · filed 2023-05-11 | 0.00 shares derived: sum of 3 quarters · filed 2023-05-11 | 5.97K shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-29 | 0.00 shares derived: sum of 2 quarters · filed 2023-03-29 | 5.97K shares derived: sum of 3 quarters · filed 2023-03-29 | 31.83K shares 10-K · filed 2023-03-29 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 5.97K shares derived: sum of 2 quarters · filed 2022-11-09 | 31.83K shares 10-Q · filed 2022-11-09 | |
| 2022-06-30 | 5.97K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 31.83K shares 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | 25.86K shares 10-Q · filed 2022-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |